ArticleSleep & breathing = Schlaf & Atmung2026
Barriers to the diagnosis and treatment of obstructive sleep apnea in 15 francophone Sub-Saharan African countries: A multicountry survey.
Article in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeObstructive sleep apnoea (OSA) is underdiagnosed and undertreated in low-resource settings. This study aimed to comprehensively assess the availability, accessibility, and affordability of diagnostic and therapeutic resources for OSA across 15 francophone sub-Saharan African (FSSA) countries.
methodsA cross-sectional survey was conducted from October to December 2025 under the coordination of the Société Africaine de Pneumologie de Langue Française (SAPLF). National experts from 15 countries were purposefully selected through the SAPLF network and completed a standardized questionnaire covering infrastructure, costs, workforce, insurance coverage, and perceived barriers. Quantitative data were analyzed descriptively; qualitative responses were analyzed thematically.
resultsPolysomnography (PSG) was available in 6/15 countries (40%) and respiratory polygraphy (RP) in 13/15 (86.7%), primarily concentrated in capital cities and private centers. Diagnostic costs were prohibitive: PSG ranged from €221-686 and RP from €69-259, often exceeding the statutory monthly minimum wage (SMW). Continuous positive airway pressure (CPAP) devices were available in 8/15 countries (53.3%) and mandibular advancement devices (MAD) in 5/15 (33.3%), with costs ranging from €381-3,812 and €38-305, respectively. Insurance coverage for CPAP was partial and reported in only three countries. The density of trained practitioners was critically low, with most countries reporting fewer than two per million inhabitants.
conclusionOSA care in francophone sub-Saharan Africa is constrained by centralised diagnostic capacity, prohibitive costs, and a shortage of trained providers. Strengthening training, reducing financial barriers, and integrating sleep medicine into non-communicable disease strategies may improve equity in access.
Indexed as
Identifiers
42809166What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.